

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-21. (Canceled)

22. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3 and comprises:

the H chain V region having the amino acid sequence of SEQ ID NO:9; and

the L chain V region having the amino acid sequence of SEQ ID NO:54

The antibody conjugate according to claim 1, wherein the humanized antibody comprises:

the H chain V region having the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence represented by SEQ ID NO:54.

23. (Currently Amended) An antibody conjugate, comprising a humanized antibody  
The antibody conjugate according to claim 1, wherein the humanized antibody is an  
antibody produced by a transformant KM8871 (FERM BP-6790) or an antibody

fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3.

Claims 24-31. (Canceled)

32. (Currently Amended) The antibody conjugate according to claim 22[[1]],  
wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence of represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence of represented by SEQ ID NO:54.

Claims 33-35. (Canceled)

36. (Currently Amended) The antibody conjugate according to claim [[1]]22,  
wherein the therapeutic agent is a cytokine.

37. (Previously Presented) The antibody conjugate according to claim 36, wherein  
the cytokine is human interleukin-2 (hIL-2).

Claims 38-39. (Canceled)

40. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3. The antibody conjugate according to claim 37, wherein the antibody

conjugate comprises a humanized antibody is produced by transformant KM8871 (FERM BP-6790) and the therapeutic agent is hIL-2.

41. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with The antibody conjugate according to claim 37, wherein the antibody conjugated with hIL-2 comprises:  
the, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3 and comprises:

the H chain V region having the amino acid sequence of represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence of represented by SEQ ID NO:54,

wherein the H chain V region conjugated with hIL-2 has the amino acid sequence of represented by SEQ ID NO:53.

Claims 42-47. (Canceled)

48. (Currently Amended) A humanized antibody or an antibody fragment thereof which specifically binds to ganglioside GD3 and comprises:

[[an]]the H chain V region having the amino acid sequence of represented by SEQ ID NO:9; and

[[an]]the L chain V region having the amino acid sequence of SEQ ID NO:10 in which at least one or more amino acid residue selected from 41<sup>st</sup> position Gly, 44<sup>th</sup> position Pro, 83<sup>rd</sup> position Phe and 87<sup>th</sup> position Tyr represented by SEQ ID NO:10 is replaced with Asp, Val, Ile and Phe, respectively.

Claims 49-57. (Canceled)

58. (Currently Amended) The humanized antibody KM8871 or the antibody fragment thereof according to claim 48 or 65-er-63, wherein the humanized antibody is an antibody produced by a transformant KM8871 (FERM BP-6790).

Claims 59-61. (Canceled)

62. (Currently Amended) A transformant KM8871 (FERM BP-6790) which produces the humanized antibody according to claim 48 or 65-er-63.

Claims 63-64. (Canceled)

65. (Currently Amended) The humanized antibody or the antibody fragment thereof according to claim 48 or-63, wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence of represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence of represented by SEQ ID NO:54.

Claims 66-68. (Canceled)

69. (Previously Presented) The antibody conjugate of claim 40, wherein the antibody conjugate is an antibody conjugate produced by a transformant KM8871hIL2 (FERM BP-6791).